[Immunosuppressive therapy as a risk factor for new-onset diabetes after transplantation].
S S AllazovaM S NovikovaO N KotenkoE M ShilovPublished in: Terapevticheskii arkhiv (2020)
13% of recipients developed de novo kidney diabetes after allograft. Age at the time of allotransplantation, gender, as well as the use of tacrolimus in combination with i-mTOR are the most significant risk factors for the development of NODAT.